Denteric enters Phase I clinical trials

27 Feb 2024

Denteric is pleased to announce that its first subjects have been dosed today in its first in human safety study of GPV381, a therapy designed to treat severe periodontal disease.  The phase 1 study will assess safety and tolerability of the therapy in healthy subjects and is being conducted at Nucleus Networks Phase I Unit in Melbourne.

Read more

Denteric awarded CUREator Grant

20 Jul 2022

Round one provided support to Denteric, an early-stage biotech developing therapies targeting  Porphyromonas gingivalis (Pg) related diseases – initially focused on severe periodontal disease.

Read more

Denteric Awarded $1.2 million CRC Grant

24 Jul 2022

Recent success with Pfizer and Moderna vaccines to Covid-19 has proven efficacy of mRNA vaccines for viruses, but little is known about using mRNA against bacterial pathogens, which are equally abundant.

Read more

Laureate Professor Eric Reynolds AO awarded the Prime Minister’s Prize for Innovation

18 Oct 2017

Denteric co-founder Professor Reynolds has been recognised for his outstanding achievement in translating scientific discoveries into globally successful products that prevent and treat oral disease.

Read more

Start-up fighting gum disease closes $14m round

Australian Financial Review
26 Sep 2019

CSL-backed biotech company Denteric has closed a $14 million funding round, enabling it to develop a vaccine for a gum disease that affects one in three adults globally, with a human clinical trial expected within three years.

Read more

$14m invested to create vaccine for debilitating periodontal gum disease

Melbourne University
26 Sep 2019

A vaccine for periodontal gum disease, which affects a third of all adults globally, is in development following a $14 million investment into newly-formed biotech company Denteric Pty Ltd.

Read more